What is the pathophysiology of a hormone-resistant prostate tumour?

European Journal of Cancer

Volumn 47, Issue SUPPL. 3, 2011, Pages

  Tombal, Bertrand ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BRCA1 PROTEIN; CALMODULIN; CYTOKERATIN 14; CYTOKERATIN 5; FIBROBLAST GROWTH FACTOR 10; HEAT SHOCK PROTEIN 90; HISTONE H4; JAGGED1; KERATINOCYTE GROWTH FACTOR; MYC PROTEIN; NUCLEAR RECEPTOR COACTIVATOR 2; ORNITHINE DECARBOXYLASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN KINASE B; PROTEIN P53; STEROID 5ALPHA REDUCTASE; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; VASCULOTROPIN;

ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL DIVISION; GENE CONTROL; GENE MUTATION; GENE OVEREXPRESSION; HORMONE RESISTANT PROSTACE CANCER; HUMAN; METASTASIS; ONCOGENE H RAS; ORCHIECTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEROIDOGENESIS; X CHROMOSOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 80053231577     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/S0959-8049(11)70163-0     Document Type: Article

References (69)

1. C Huggins, C Hodges Studies on prostate cancer. I. The effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293
2. C Huggins Endocrine-induced regression of cancers Cancer Res 27 ll 1967 1925 1930
3. JT Isaacs, DS Coffey Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma Cancer Res 41 12Pt l 1981 5070 5075 (Pubitemid 12196676)
4. EP Gelmann Molecular biology of the androgen receptor J Clin Oncol 20 13 2002 3001 3015 (Pubitemid 34728896)
5. CA Heinlein, C Chang Androgen receptor (AR) coregulators: an overview Endocrine Rev 23 2 2002 175 200 (Pubitemid 34299023)
6. IV Litvinov, AM De Marzo, JT Isaacs Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88 7 2003 2972 2982 (Pubitemid 36877458)
7. RR Berges, J Vukanovic, JI Epstein et al. Implication of cell kinetic changes during the progression of human prostatic cancer Clin Cancer Res 1 5 1995 473 480
8. D Vander Griend, J d'Antonio, J Isaacs Hormonal regulation of the prostate R Berges B Tombal Androgens and Prostate Cancer 2009 ISMAR Healthcare Lier, Belgium 11 34
9. MS Wicha, S Liu, G Dontu Cancer stem cells: an old idea -a paradigm shift Cancer Res 66 4 2006 1883 1890 discussion: 1895-6.
10. AM De Marzo, MJ Putzi, WG Nelson New concepts in the pathology of prostatic epithelial carcinogenesis Urology 57 4Suppll 2001 103 114
11. SA Tomlins, A Bjartell, AM Chinnaiyan et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice Eur Urol 56 2 2009 275 286
12. SA Tomlins, DR Rhodes, S Perner et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 5748 2005 644 648 (Pubitemid 41528150)
13. MM Shen, C Abate-Shen Molecular genetics of prostate cancer: new prospects for old challenges Genes Dev 24 18 2010 1967 2000
14. N Kyprianou, JT Isaacs Activation of programmed cell death in the rat ventral prostate after castration Endocrinology 122 2 1988 552 562 (Pubitemid 18060946)
15. C Abate-Shen, MM Shen Molecular genetics of prostate cancer Genes Dev 14 19 2000 2410 2434
16. N Kyprianou, JT Isaacs Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death Mol Endocrinol 3 10 1989 1515 1522 (Pubitemid 19260400)
17. G Yan, Y Fukabori, S Nikolaropoulos, F Wang, WL McKeehan Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin Mol Endocrinol 6 12 1992 2123 2128 (Pubitemid 23021561)
18. SR Denmeade, B Tombal, JT Isaacs Apoptotic pathways in prostate cancer MP Mattson S Estus VM Rangnekar Programmed cell death Vol. II 2001 Elsevier Amsterdam 23 54 (Pubitemid 33805613)
19. N Kyprianou, JT Isaacs "Thymineless" death in androgen-independent prostatic cancer cells Biochem Biophys Res Commun 165 1 1989 73 81 (Pubitemid 20012456)
20. CL Tso, WH McBride, J Sun et al. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells Cancer J 6 4 2000 220 233
21. DG Bostwick, A Shan, J Qian et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma Cancer 83 9 1998 1995 2002 (Pubitemid 28503732)
22. N Craft, C Chhor, C Tran et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process Cancer Res 59 19 1999 5030 5036 (Pubitemid 29472911)
23. R Mehra, SA Tomlins, J Yu et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer Cancer Res 68 10 2008 3584 3590
24. RB Shah, R Mehra, AM Chinnaiyan et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program Cancer Res 64 24 2004 9209 9216 (Pubitemid 39665537)
25. J Isaacs Control of cell proliferation and cell death in the normal and neoplastic prostate: A stem cell model CH Rodgers DS Coffey G Cunha Benign prostatic hyperplasia 1985 Department of Health and Human Services Washington, DC 85 94
26. PA Abrahamsson Neuroendocrine cells in tumour growth of the prostate Endocr Relat Cancer 6 4 1999 503 519
27. T Fixemer, K Remberger, H Bonkhoff Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma Prostate 53 2 2002 118 123
28. L Cindolo, M Cantile, F Vacherot, S Terry, A de la Taille Neuroendocrine differentiation in prostate cancer: from lab to bedside Urollnt 79 4 2007 287 296 (Pubitemid 350136512)
29. M Shackleton, E Quintana, ER Fearon, SJ Morrison Heterogeneity in cancer: cancer stem cells versus clonal evolution Cell 138 5 2009 822 829
30. W Huang, M Waknitz ETS gene fusions and prostate cancer Am J Trans Res 1 4 2009 341 351
31. D Sarker, AH Reid, TA Yap, JS de Bono Targeting the PI3K/AKT pathway for the treatment of prostate cancer Clin Cancer Res 15 15 2009 4799 4805
32. DJ Mulholland, S Dedhar, H Wu, CC Nelson PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer Oncogene 25 3 2006 329 337 (Pubitemid 43117618)
33. J Bertram, JW Peacock, L Fazli et al. Loss of PTEN is associated with progression to androgen independence Prostate 66 9 2006 895 902 (Pubitemid 43849588)
34. IN Holcomb, JM Young, IM Coleman et al. Comparative analyses of chromosome alterations in soft-tissue métastases within and across patients with castration-resistant prostate cancer Cancer Res 69 19 2009 7793 7802
35. G Attard, JF Swennenhuis, D Olmos et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 7 2009 2912 2918
36. S Jia, Z Liu, S Zhang et al. Essential roles of PI(3)K-pll0beta in cell growth, metabolism and tumorigenesis Nature 454 7205 2008 776 779
37. Y Furuya, S Krajewski, JI Epstein, JC Reed, JT Isaacs Expression of bcl-2 and the progression of human and rodent prostatic cancers Clin Cancer Res 2 2 1996 389 398 (Pubitemid 26075642)
38. M Gleave, A Tolcher, H Miyake et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model Clin Cancer Res 5 10 1999 2891 2898 (Pubitemid 29493968)
39. G Attard, CS Cooper, JS de Bono Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16 6 2009 458 462
40. H Bonkhoff, R Berges From pathogenesis to prevention of castration resistant prostate cancer Prostate 70 1 2010 100 112
41. ME Taplin Androgen receptor: role and novel therapeutic prospects in prostate cancer Expert Rev Anticancer Ther 8 9 2008 1495 1508
42. CW Gregory, KG Hamil, D Kim et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes Cancer Res 58 24 1998 5718 5724 (Pubitemid 29006412)
43. P Koivisto, J Kononen, C Palmberg et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Res 57 2 1997 314 319 (Pubitemid 27036612)
44. MJ Linja, KJ Savinainen, OR Saramaki, TL Tammela, RL Vessella, T Visakorpi Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer Cancer Res 61 9 2001 3550 3555 (Pubitemid 32694958)
45. T Visakorpi, E Hyytinen, P Koivisto et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nat Genet 9 4 1995 401 406
46. C Palmberg, P Koivisto, L Kakkola, TL Tammela, OP Kallioniemi, T Visakorpi Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer J Urol 164 6 2000 1992 1995
47. CD Chen, DS Welsbie, C Tran et al. Molecular determinants of resistance to antiandrogen therapy Nat Med 10 l 2004 33 39 (Pubitemid 38524696)
48. CW Gregory, RT Johnson Jr, JL Mohler, FS French, EM Wilson Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen Cancer Res 61 7 2001 2892 2898 (Pubitemid 32691931)
49. M Shiota, A Yokomizo, S Naito Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target J Mol Endocrinol 2011
50. C Tran, S Ouk, NJ Clegg et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 5928 2009 787 790
51. GN Brooke, MG Parker, CL Bevan Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression Oncogene 27 21 2008 2941 2950 (Pubitemid 351668003)
52. K Robzyk, H Oen, G Buchanan et al. Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor Mol Cell Endocrinol 268 l-2 2007 67 74 (Pubitemid 46437353)
53. MP Steinkamp, OA O'Mahony, M Brogley et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy Cancer Res 69 10 2009 4434 4442
54. ME Taplin, GJ Bubley, TD Shuster et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N Engl J Med 332 21 1995 1393 1398
55. XY Zhao, PJ Malloy, AV Krishnan et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 6 6 2000 703 706 (Pubitemid 30398797)
56. J Ceraline, MD Crachant, E Erdmann et al. Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer Int J Cancer 108 l 2004 152 157 (Pubitemid 37444458)
57. ZX Zhou, M Sar, JA Simental, MV Lane, EM Wilson A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences JBiol Chem 269 18 1994 13115 13123
58. R Hu, TA Dunn, S Wei et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer Cancer Res 69 1 2009 16 22
59. PA Watson, YF Chen, MD Balbas et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor Proc Nati AcadSci USA 107 39 2010 16759 16765
60. E Hornberg, EB Ylitalo, S Crnalic et al. Expression of androgen receptor splice variants in prostate cancer bone métastases is associated with castration-resistance and short survival PloS ONE 6 4 2011 el9059
61. A Urbanucci, KK Waltering, HE Suikki, MA Helenius, T Visakorpi Androgen regulation of the androgen receptor coregulators BMC Cancer 8 2008 219
62. JA Locke, ES Guns, AA Lubik et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res 68 15 2008 6407 6415
63. RB Montgomery, EA Mostaghel, R Vessella et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 ll 2008 4447 4454
64. M Stanbrough, GJ Bubley, K Ross et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 5 2006 2815 2825
65. MA Titus, MJ Schell, FB Lih, KB Tomer, JL Mohler Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer Clin Cancer Res 11 13 2005 4653 4657 (Pubitemid 41557182)
66. F Labrie, A Dupont, A Bélanger Complete androgen blockade for the treatment of prostate cancer Important Adv Oncol 1985 193 217
67. CW Gregory, X Fei, LA Ponguta et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer J Biol Chem 279 8 2004 7119 7130 (Pubitemid 38248859)
68. T Ueda, NR Mawji, N Brachovsky, MD Sadar Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells JBiol Chem 277 41 2002 38087 38094 (Pubitemid 35157768)
69. SL Krueckl, RA Sikes, NM Edlund et al. Increased insulinlike growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model Cancer Res 64 23 2004 8620 8629 (Pubitemid 39552075)